The U.S. Supreme Court’s January decision in Teva v. Sandoz ordering more deference to trial judges on claim construction was expected to have a big impact on patent litigation.

But some academics questioned how much the decision—which requires the Federal Circuit to review factual findings for clear error but still allows independent review of legal conclusions—would actually change outcomes on appeal.